10:23 AM EDT, 10/17/2024 (MT Newswires) -- Tevogen Bio Holdings ( TVGN ) said Thursday it expects to generate $1 billion in revenue from its oncology pipeline in the launch year, with cumulative five-year revenues projected between $10 billion and $14 billion.

Part of the forecast is TVGN 489 for the treatment of severe acute respiratory syndrome coronavirus 2 infection in patients with B cell hematologic cancer and patients with other cancers, the company said.

Shares of Tevogen Bio ( TVGN ) soared 46% in recent trading.

Price: 1.52, Change: +0.48, Percent Change: +46.06